JP2021532058A5 - - Google Patents
Info
- Publication number
- JP2021532058A5 JP2021532058A5 JP2020552889A JP2020552889A JP2021532058A5 JP 2021532058 A5 JP2021532058 A5 JP 2021532058A5 JP 2020552889 A JP2020552889 A JP 2020552889A JP 2020552889 A JP2020552889 A JP 2020552889A JP 2021532058 A5 JP2021532058 A5 JP 2021532058A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- acid sequence
- antibody
- variable region
- chain variable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024027487A JP2024063083A (ja) | 2018-07-25 | 2024-02-27 | 抗ｔｉｇｉｔ抗体及びその使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810823583 | 2018-07-25 | ||
| CN201810823583.6 | 2018-07-25 | ||
| PCT/CN2019/097665 WO2020020281A1 (zh) | 2018-07-25 | 2019-07-25 | 抗tigit抗体及其用途 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024027487A Division JP2024063083A (ja) | 2018-07-25 | 2024-02-27 | 抗ｔｉｇｉｔ抗体及びその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021532058A JP2021532058A (ja) | 2021-11-25 |
| JP2021532058A5 true JP2021532058A5 (enExample) | 2022-07-28 |
| JP7524065B2 JP7524065B2 (ja) | 2024-07-29 |
Family
ID=69181312
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020552889A Active JP7524065B2 (ja) | 2018-07-25 | 2019-07-25 | 抗ｔｉｇｉｔ抗体及びその使用 |
| JP2024027487A Withdrawn JP2024063083A (ja) | 2018-07-25 | 2024-02-27 | 抗ｔｉｇｉｔ抗体及びその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024027487A Withdrawn JP2024063083A (ja) | 2018-07-25 | 2024-02-27 | 抗ｔｉｇｉｔ抗体及びその使用 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US11370837B2 (enExample) |
| EP (1) | EP3838289A4 (enExample) |
| JP (2) | JP7524065B2 (enExample) |
| KR (1) | KR20210040827A (enExample) |
| CN (1) | CN112135626B (enExample) |
| AU (1) | AU2019310803B2 (enExample) |
| BR (1) | BR112021001201A2 (enExample) |
| CA (1) | CA3092456C (enExample) |
| SG (1) | SG11202100746WA (enExample) |
| TW (1) | TWI754157B (enExample) |
| WO (1) | WO2020020281A1 (enExample) |
| ZA (1) | ZA202100676B (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021113831A1 (en) | 2019-12-05 | 2021-06-10 | Compugen Ltd. | Anti-pvrig and anti-tigit antibodies for enhanced nk-cell based tumor killing |
| CN115052622B (zh) * | 2020-01-21 | 2026-03-06 | 夏尔巴生物技术(杭州)有限公司 | 重组全人源抗tigit单克隆抗体制剂及其制备方法和用途 |
| CN111995681B (zh) * | 2020-05-09 | 2022-03-08 | 华博生物医药技术（上海）有限公司 | 抗tigit的抗体、其制备方法和应用 |
| TW202210514A (zh) | 2020-06-02 | 2022-03-16 | 美商阿克思生物科學有限公司 | 針對tigit的抗體 |
| WO2021257124A1 (en) | 2020-06-18 | 2021-12-23 | Genentech, Inc. | Treatment with anti-tigit antibodies and pd-1 axis binding antagonists |
| TW202216778A (zh) | 2020-07-15 | 2022-05-01 | 美商安進公司 | Ｔｉｇｉｔ及ｃｄ１１２ｒ阻斷 |
| EP4219553A4 (en) * | 2020-09-22 | 2024-11-27 | Nanjing Sanhome Pharmaceutical Co., Ltd. | ANTI-TIGIT ANTIBODIES AND DUAL ANTIBODIES AND THEIR APPLICATION |
| US20240002500A1 (en) * | 2020-11-23 | 2024-01-04 | Guangdong Fapon Biopharma Inc. | Anti-TIGIT Antibody or Antigen-Binding Fragment Thereof |
| WO2022124864A1 (ko) * | 2020-12-10 | 2022-06-16 | 주식회사 유틸렉스 | 항-tigit 항체 및 이의 용도 |
| JP2024514974A (ja) * | 2021-04-26 | 2024-04-03 | メモリアル スローン－ケタリング キャンサー センター | Ａｄｇｒｅ２及び／またはｃｌｅｃ１２ａを標的とするキメラ受容体及びその使用 |
| US12558406B2 (en) | 2021-05-10 | 2026-02-24 | Medimabbio Inc. | Anti-TIGIT antibodies and use thereof |
| CN118871463A (zh) | 2021-07-28 | 2024-10-29 | 基因泰克公司 | 用于治疗癌症的方法和组合物 |
| KR20240043786A (ko) * | 2021-08-09 | 2024-04-03 | 바이오세우스 인크. | 항-tigit 항체 및 이의 용도 |
| WO2023056403A1 (en) | 2021-09-30 | 2023-04-06 | Genentech, Inc. | Methods for treatment of hematologic cancers using anti-tigit antibodies, anti-cd38 antibodies, and pd-1 axis binding antagonists |
| WO2023108609A1 (en) * | 2021-12-17 | 2023-06-22 | Shanghai Nigene Biological Science And Technology Co., Ltd. | Tigit antibodies and uses thereof |
| CN120590537A (zh) * | 2021-12-31 | 2025-09-05 | 南京维立志博生物科技股份有限公司 | 靶向tigit的双特异性抗体 |
| CA3259975A1 (en) | 2022-03-15 | 2023-09-21 | Compugen Ltd. | Il-18bp antagonist antibodies and their use in monotherapy and combination therapy in the treatment of cancer |
| CN119156228A (zh) | 2022-05-02 | 2024-12-17 | 艾库斯生物科学有限公司 | 抗tigit抗体及其用途 |
| JP2025523387A (ja) | 2022-06-07 | 2025-07-23 | ジェネンテック， インコーポレイテッド | 抗ｐｄ－ｌ１アンタゴニストおよび抗ｔｉｇｉｔアンタゴニスト抗体を含む、肺がん治療の有効性を判定するための方法 |
| US20240309052A1 (en) * | 2023-03-16 | 2024-09-19 | Sunnybrook Research Institute | Constructs, use and methods thereof |
| TW202515608A (zh) | 2023-06-26 | 2025-04-16 | 以色列商坎布根有限公司 | Ｉｌ—１８ｂｐ拮抗抗體及其於癌症治療之單一療法及組合療法的用途 |
| CN121003695A (zh) * | 2024-05-24 | 2025-11-25 | 百奥泰生物制药股份有限公司 | 抗tigit抗体和抗pd-1抗体联合治疗肿瘤 |
Family Cites Families (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3572982D1 (en) | 1984-03-06 | 1989-10-19 | Takeda Chemical Industries Ltd | Chemically modified lymphokine and production thereof |
| US4737456A (en) | 1985-05-09 | 1988-04-12 | Syntex (U.S.A.) Inc. | Reducing interference in ligand-receptor binding assays |
| US5677425A (en) | 1987-09-04 | 1997-10-14 | Celltech Therapeutics Limited | Recombinant antibody |
| EP0401384B1 (en) | 1988-12-22 | 1996-03-13 | Kirin-Amgen, Inc. | Chemically modified granulocyte colony stimulating factor |
| GB9108652D0 (en) | 1991-04-23 | 1991-06-12 | Antisoma Ltd | Immunoreactive compounds |
| EP0604580A1 (en) | 1991-09-19 | 1994-07-06 | Genentech, Inc. | EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab') 2? ANTIBODIES |
| AU686113B2 (en) | 1992-09-16 | 1998-02-05 | Scripps Research Institute, The | Human neutralizing monoclonal antibodies to respiratory syncytial virus |
| JP3919830B2 (ja) | 1992-11-28 | 2007-05-30 | 財団法人化学及血清療法研究所 | 抗ネコヘルペスウイルス−１組換え抗体および該抗体をコードする遺伝子断片 |
| WO1995018634A1 (en) | 1994-01-04 | 1995-07-13 | The Scripps Research Institute | Human monoclonal antibodies to herpes simplex virus and methods therefor |
| US5789199A (en) | 1994-11-03 | 1998-08-04 | Genentech, Inc. | Process for bacterial production of polypeptides |
| US5840523A (en) | 1995-03-01 | 1998-11-24 | Genetech, Inc. | Methods and compositions for secretion of heterologous polypeptides |
| US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
| US6090382A (en) | 1996-02-09 | 2000-07-18 | Basf Aktiengesellschaft | Human antibodies that bind human TNFα |
| US6171586B1 (en) | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
| CA2323757C (en) | 1998-04-02 | 2011-08-02 | Genentech, Inc. | Antibody variants and fragments thereof |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| GB9814383D0 (en) | 1998-07-02 | 1998-09-02 | Cambridge Antibody Tech | Improvements relating to antibodies |
| JP4593783B2 (ja) | 1998-07-21 | 2010-12-08 | ゲンマブ・アクティーゼルスカブ | 抗ｃ型肝炎ウイルス抗体およびその使用 |
| US6914128B1 (en) | 1999-03-25 | 2005-07-05 | Abbott Gmbh & Co. Kg | Human antibodies that bind human IL-12 and methods for producing |
| US6818216B2 (en) | 2000-11-28 | 2004-11-16 | Medimmune, Inc. | Anti-RSV antibodies |
| SE526864C2 (sv) | 2004-07-05 | 2005-11-15 | Svensk Roekgasenergi Intressen | Förfarande och anordning för avskiljning av föroreningar ur ett gasflöde |
| JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
| EP3683230A1 (en) | 2005-05-12 | 2020-07-22 | ZymoGenetics, Inc. | Compositions and methods for modulating immune responses |
| WO2009036379A2 (en) | 2007-09-14 | 2009-03-19 | Adimab, Inc. | Rationally designed, synthetic antibody libraries and uses therefor |
| US8877688B2 (en) | 2007-09-14 | 2014-11-04 | Adimab, Llc | Rationally designed, synthetic antibody libraries and uses therefor |
| US9266967B2 (en) | 2007-12-21 | 2016-02-23 | Hoffmann-La Roche, Inc. | Bivalent, bispecific antibodies |
| US8242247B2 (en) | 2007-12-21 | 2012-08-14 | Hoffmann-La Roche Inc. | Bivalent, bispecific antibodies |
| US8227577B2 (en) | 2007-12-21 | 2012-07-24 | Hoffman-La Roche Inc. | Bivalent, bispecific antibodies |
| US20090162359A1 (en) | 2007-12-21 | 2009-06-25 | Christian Klein | Bivalent, bispecific antibodies |
| BRPI1014089A2 (pt) | 2009-04-02 | 2016-04-19 | Roche Glycart Ag | anticorpos multiespecíficos que compreendem anticorpos de comprimento completo e fragmentos fab de cadeia simples |
| PT2417156E (pt) | 2009-04-07 | 2015-04-29 | Roche Glycart Ag | Anticorpos trivalentes, biespecíficos |
| SG176219A1 (en) | 2009-05-27 | 2011-12-29 | Hoffmann La Roche | Tri- or tetraspecific antibodies |
| US9676845B2 (en) | 2009-06-16 | 2017-06-13 | Hoffmann-La Roche, Inc. | Bispecific antigen binding proteins |
| US8703132B2 (en) | 2009-06-18 | 2014-04-22 | Hoffmann-La Roche, Inc. | Bispecific, tetravalent antigen binding proteins |
| MX381912B (es) | 2010-07-16 | 2025-03-13 | Adimab Llc | Colecciones de anticuerpos. |
| TWI888366B (zh) | 2013-07-16 | 2025-07-01 | 美商建南德克公司 | 利用pd-1軸結合拮抗劑及tigit抑制劑治療癌症之方法 |
| SG11201607969XA (en) | 2014-03-31 | 2016-10-28 | Genentech Inc | Anti-ox40 antibodies and methods of use |
| CA2957722C (en) * | 2014-08-19 | 2022-05-31 | Merck Sharp & Dohme Corp. | Anti-tigit antibodies |
| AR103268A1 (es) | 2014-12-23 | 2017-04-26 | Bristol Myers Squibb Co | Anticuerpos contra tigit |
| TWI715587B (zh) * | 2015-05-28 | 2021-01-11 | 美商安可美德藥物股份有限公司 | Ｔｉｇｉｔ結合劑和彼之用途 |
| WO2017024465A1 (en) | 2015-08-10 | 2017-02-16 | Innovent Biologics (Suzhou) Co., Ltd. | Pd-1 antibodies |
| CN115925931A (zh) * | 2015-08-14 | 2023-04-07 | 默沙东公司 | 抗tigit抗体 |
| US10946095B2 (en) * | 2015-09-02 | 2021-03-16 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Antibodies specific to human T-cell immunoglobulin and ITIM domain (TIGIT) |
| SG10202007764TA (en) | 2015-09-25 | 2020-09-29 | Genentech Inc | Anti-tigit antibodies and methods of use |
| PT3356413T (pt) | 2015-10-01 | 2022-04-04 | Potenza Therapeutics Inc | Proteínas de ligação a antigénio anti-tigit e métodos de utilização das mesmas |
| WO2017132827A1 (en) | 2016-02-02 | 2017-08-10 | Innovent Biologics (Suzhou) Co., Ltd. | Pd-1 antibodies |
| MX2018010485A (es) | 2016-03-04 | 2019-01-10 | Jn Biosciences Llc | Anticuerpos para inmunoreceptor de celulas t con dominios de ig e itim (tigit). |
-
2019
- 2019-07-25 TW TW108126351A patent/TWI754157B/zh not_active IP Right Cessation
- 2019-07-25 CA CA3092456A patent/CA3092456C/en active Active
- 2019-07-25 JP JP2020552889A patent/JP7524065B2/ja active Active
- 2019-07-25 SG SG11202100746WA patent/SG11202100746WA/en unknown
- 2019-07-25 AU AU2019310803A patent/AU2019310803B2/en not_active Ceased
- 2019-07-25 CN CN201980022679.5A patent/CN112135626B/zh active Active
- 2019-07-25 US US16/965,687 patent/US11370837B2/en not_active Expired - Fee Related
- 2019-07-25 KR KR1020207028253A patent/KR20210040827A/ko not_active Withdrawn
- 2019-07-25 EP EP19842191.9A patent/EP3838289A4/en not_active Withdrawn
- 2019-07-25 WO PCT/CN2019/097665 patent/WO2020020281A1/zh not_active Ceased
- 2019-07-25 BR BR112021001201-0A patent/BR112021001201A2/pt unknown
-
2021
- 2021-01-29 ZA ZA2021/00676A patent/ZA202100676B/en unknown
-
2024
- 2024-02-27 JP JP2024027487A patent/JP2024063083A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN112135626A (zh) | 抗tigit抗体及其用途 | |
| JP6719477B2 (ja) | 抗ｔｉｍ−３抗体 | |
| JP6701213B2 (ja) | 抗ｐｄ−１抗体 | |
| JP6709215B2 (ja) | 抗ｔｉｍ−３抗体 | |
| FI3322727T3 (fi) | Humanisoituja tai kimeerisiä CD3-vasta-aineita | |
| CN110536903A (zh) | 抗ox40抗体及其用途 | |
| JP2019201643A5 (enExample) | ||
| JP2020048564A5 (enExample) | ||
| JP2020515247A5 (enExample) | ||
| JP2021515565A5 (enExample) | ||
| JP2021533726A5 (enExample) | ||
| RU2017145150A (ru) | Антитело против pdl-1, его фармацевтическая композиция и применение | |
| JP2018526981A5 (enExample) | ||
| JP2018532383A5 (enExample) | ||
| RU2011128399A (ru) | Антитела к pd-l1 и их применение для усиления функции т-клеток | |
| EP2928919A2 (en) | Blood-brain barrier (bbb) penetrating dual specific binding proteins | |
| FI3561057T3 (fi) | Anti-cd3-vasta-aine ja vasta-ainetta sisältäviä molekyylejä | |
| RU2015130626A (ru) | КОМПОЗИЦИИ АНТИТЕЛА К ИНТЕГРИНУ β1 И СПОСОБЫ ИХ ПРИМЕНЕНИЯ | |
| JP2021530244A5 (enExample) | ||
| JP2025500796A5 (enExample) | ||
| CN111886023A (zh) | 针对tim-3的抗体及其用途 | |
| RU2019135404A (ru) | Антитела для лечения инфекции гепатитом в и связанных с ней заболеваний | |
| AU2021255884A1 (en) | Anti-FLT3 antibodies and compositions | |
| JP2022517216A5 (enExample) | ||
| JP2024500512A5 (enExample) |